Nilotinib i dazatinibv 1-y linii terapii bol'nykhkhronicheskim mieloleykozomv khronicheskoy faze

by N S Lazorko, E G Lomaia, E I Sbityakova, A Yu Zaritskiy
Published 2011-06-01

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia

by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy
Published 2014-07-01

Effektivnost' zatrat nabendamustin v terapii indolentnykhnekhodzhkinskikh limfom

by A V Rudakova, I V Poddubnaya, A Yu Zaritskiy, E A Stadnik
Published 2011-06-01

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia

by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy
Published 2014-07-01

Molekulyarnyy monitoringeffektivnosti terapii bol'nykhkhronicheskim mieloleykozom v Rossii(po materialam Vserossiyskoy nauchno-prakticheskoykonferentsii, Irkutsk, 3-4 sentyabrya 20...

by M V Dubina, D A Kuevda, T E Khomyakova, G A Tsaur, S I Kutsev, A Yu Zaritskiy
Published 2010-12-01

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia

by E A Stadnik, V V Strugov, T O Andreeva, Yu V Virts, Yu V Mirolyubova, P A Butylin, A Yu Zaritskiy
Published 2016-12-01

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS

by E. G. lisina, N. T. Siordiya, P. A. Butylin, A. A. Silyutina, N. M. Matyukhina, O. M. Senderova, E. S. Fokina, V. A. Ovsepyan, E. G. Lomaia, A. Yu. Zaritskiy
Published 2017-10-01

Sravnenie effektivnosti i toksichnosti rezhimov FC i FCR u pervichnykh bol'nykhV-kletochnym khronicheskim limfoleykozom

by E A Stadnik, E A Nikitin, B V Biderman, G N Salogub, Yu Yu Lorie, N N Tsyba, Yu A Alekseeva, V A Doronin, V N Mashchuk, R I Vabishchevich, A L Melikyan, T I Kolosheynova, L Yu Kolosova, A B Sudarikov, L G Kovaleva, A Yu Zaritskiy
Published 2008-09-01